Logo
Tuesday, 07 July 2020
Logo
The News and Media Division of The Insight Partners
Friday, 05 Jun 2020 03:00 pm

Healios Successfully Establishes Proprietary Universal Donor Cell Research Line

Healios K.K., Japan's clinical-stage biotechnology company, has been creating Universal Donor Cells (UDCs), which are next-generation iPS cells created with gene-editing technology to engineer a low risk of immune rejection (*1) regardless of HLA types (*2). The Company is pleased to announce that it has successfully established a proprietary UDC research line and characterized its gene expression and other features.

newsImage
 

Healios plans to combine its UDC technology with its existing efforts in next-generation cancer-targeting immune cells, ophthalmology, organ buds and so on to create a line of regenerative medicine therapies with the highest possible safety and efficacy profile.

Typically, transplanted cells trigger an immune rejection response in patients whose HLA type does not match that of the cells. Therefore, doctors must administer an immunosuppressant drug during transplantation, which increases the burden on the patient's body. To avoid the administration of immunosuppressants, it is preferable to utilize autologous iPS cells produced by the patient's own cells, but the production process both takes a long time and is very expensive.

UDCs are iPS cells created using gene-editing technology that allows them to reduce the body's immune rejection response. The production of Healios' UDCs involves the removal of certain HLA genes that elicit a rejection response, the introduction of an immunosuppression gene to improve immune evasion, and the addition of a suicide gene serving as a safety mechanism, each in an allogeneic iPS cell. This next-generation technology platform allows for the creation of regenerative pharmaceutical products with enhanced safety and a lower risk of immune rejection, while preserving the inherent ability of iPS cells to replicate themselves continuously and their pluripotency in differentiating into various other kinds of cells.

Plans are underway at Healios to promote the internal development of regenerative pharmaceutical products that utilize UDCs and further reinforce the Company's pipeline. It is committed to working towards the early completion of a clinical-grade UDC line that meets global approvability standards.

Tags Healios Universal Donor Cell Japan iPS cells Gene editing Cancer

Neha Pandey

Aware of her elements, Neha writes the best articles across industries including electronics & semiconductors, automotive & transportation and food & beverages. Being from the finance background she has the ability to understand the dynamics of every industry and analyze the news updates to form insightful articles. Neha is an energetic person interested in music, travel, and entertainment. Since past 5 years, she written extensively on sectors like technology, finance and healthcare.


Smarter Decisions with Smart News

Smart Market News is committed to getting its readers the latest updates and insights on industries that help in making “smarter” business decisions. With insights and inputs from corporate decision makers, we bring you the stories of adopting innovative solutions and strategies that have been changing the world. Our editorial insights on products, solutions, companies, and adoption of best practices not only help in understanding the markets better, but also prove to be a complete package for your information needs.

media@smartmarketnews.com | sales@smartmarketnews.com

Contact Us
Subscribe to our newsletter
Get the latest in your inbox weekly Sign up for the fully charged newsletter
Follow Us:
© The News and Media Division of The Insight Partners 2019 | All Rights Reserved | Privacy Policy